NCT03878537 is a clinical trial in Non Small Cell Lung Cancer, sponsored by Scripps Translational Science Institute.

Who is sponsoring NCT03878537?

NCT03878537 is sponsored by Scripps Translational Science Institute.

What condition does NCT03878537 study?

NCT03878537 studies Non Small Cell Lung Cancer.

Is NCT03878537 still recruiting?

NCT03878537 is currently status unknown. Last updated 23 March 2021.

Last reviewed 2021-03-23 · How we verify

NCT03878537

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recurrence Monitoring in NSCLC Using Circulating Tumor DNA

Status unknown Last updated 23 March 2021

What this trial tests

trial in Non Small Cell Lung Cancer in 50 participants. Status unknown.

Timeline

14 March 2019

Primary endpoint
1 March 2021

31 December 2021

Quick facts

Lead sponsor	Scripps Translational Science Institute
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	14 March 2019
Primary completion	1 March 2021
Estimated completion	31 December 2021
Sites	1 location across United States

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Scripps Translational Science Institute

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Scripps Translational Science Institute trials

Trials by the same sponsor.

NCT06244940 — The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study · NA · recruiting
NCT05741112 — The Long COVID-19 Wearable Device Study · NA · recruiting
NCT05655546 — ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals · NA · terminated
NCT05197738 — Research Framework Exploring Sleep Health · recruiting
NCT04881019 — PRediction Of Glycemic RESponse Study · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03878537 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Scripps Translational Science Institute
Last refreshed: 23 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03878537.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing